Table 1.
Basal characteristics of patients (N = 100).
| Characteristics | N = 100 |
|---|---|
| Age, years | |
| Median (Range) | 54 (29~79) |
| Initial FIGO stage, n (%) | |
| IA | 1 (1.0) |
| IB | 1 (1.0) |
| IC | 6 (6.0) |
| IIA | 1 (1.0) |
| IIB | 3 (3.0) |
| IIIA | 2 (2.0) |
| IIIB | 6 (6.0) |
| IIIC | 47 (47.0) |
| IV | 33 (33.0) |
| Initial residual status, n (%) | |
| No residual | 41 (41.0) |
| 0.1~1 cm | 45 (45.0) |
| >1 cm | 13 (13.0) |
| Initial CA-125 level | 720.5 (14.2~11,552.2) |
| Concurrent breast cancer, n (%) | 18 (18.0) |
| Family history of breast and ovarian cancer, n (%) | 23 (23.0) |
| Platinum-free interval Duration, n (%) | |
| 6–12 months | 32 (32.0) |
| >12 months | 68 (68.0) |
| Median (range), months | 14.6 (6.0~86.3) |
| Objective response to most recent chemotherapy, n (%) | |
| Complete | 46 (46.0) |
| Partial | 53 (53.0) |
| Unknown | 1 (1.0) |
| Number of previous chemotherapy regimen, n (%) | |
| 2 | 63 (63.0) |
| 3 | 26 (26.0) |
| 4 | 7 (7.0) |
| ≥5 | 4 (4.0) |
| Median (range) | 2 (2~13) |
| Previous bevacizumab exposure, n (%) | 16 (16.0) |
| BRCA mutation status, n (%) | |
| Germline | |
| BRCA1 | 69 (69.0) |
| BRCA2 | 24 (2.0) |
| BRCA1/2 | 1 (1.0) |
| Somatic | |
| BRCA1 | 3 (3.0) |
| BRCA2 | 1 (1.0) |
| BRCA1/2 | 2 (2.0) |
FIGO: International Federation of Gynecology and Obstetrics.